Article

Socioeconomic Factors Seen to Impact Multiple Myeloma Survival

Factors other than race or ethnicity influence outcomes in multiple myeloma.

Findings from a recent study suggest that socioeconomic factors could potentially play more of a role in the survival of patients with multiple myeloma than race or ethnicity.

Recently, advances in multiple myeloma treatments have improved survival among young, white patients, but have not impacted the survival of patients of other ethnicities. The researchers suggest that socioeconomic differences explain this discrepancy rather than race, according to a study published by Cancer.

Included in the study were more than 10,000 patients with multiple myeloma, younger than 65-years-old. It was discovered that adverse socioeconomic factors, such as marital status, income, and insurance status, affected patient survival.

The 4-year estimated survival was 71.1%, 63.2%, 53.4%, and 46.5% for patients with 0, 1, 2, or 3 adverse sociodemographic factors, respectively. A married patient living in a medium-to-high income county who had private insurance was 25% more likely to be alive after 4 years than an unmarried patient who lived in a low-income county and was enrolled in Medicaid, the researchers found.

“This finding strongly suggests that there is a huge disparity in outcomes that could potentially be overcome by improving access and affordability of treatments,” said lead researcher Luciano Costa, MD, PhD. “With the recent emphasis on comparative effectiveness in oncology, it also becomes crucial that all variables affecting outcomes - including sociodemographic factors - are accounted for when comparisons between different therapeutic approaches and health care systems are made.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com